reason report
strength scale end-market continu drive
bottom line remain outperform-r given view
life scienc tool lst leader unmatch scale
reach research lab grow portfolio serv
key end-market lead consolid posit deliv
impress y/i organ revenu growth end-market
solid pharma strength notabl dd growth hsd y/i
industrial-appli lsd academic/gov msd diagnost dx
market china standout y/i growth essenti
confirm view challeng mp uniqu
compani read sector though point
mute europ still deliv msd region well
north america though see stronger y/i growth comp
still believ abl deliv in-lin like msd
growth outlook given high growth profil rais pt
strong growth broad-bas across major end-market
continu year key segment
dx lab product servic lp contribut
strength qtr given sheer size posit lst market
investor believ like pay closer attent tougher comp
emerg limit chang tariff believ
could deliv growth gener dri powder
avail execut deal drive growth accret
model lt continu put capit work repay
debt repurchas stock beyond pay cash
brammer drive growth gene cell therapi
agre acquir brammer cash rev
industry-lead viral vector manufactur support biotech pharma
gene cell therapi uniqu strateg posit given experi
multipl differ type virus brammer expect grow
contract develop manufactur organ
presenc gene therapi market svb leerink estim
grow includ pharma servic busi post
growth china still strong limit chang tariff
expect china challeng point declin
china specif deliv growth
china reflect continu opportun materi scienc
biolog research believ investor watch tariff close
net debt total capit
price-to-earnings lt ep growth
life scienc tool diagnost
year price history/av daili volume mil
compani inform svb leerink llc research
revenu ep exclud charg amort intang
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
despit reiter estimate impact plan off-set
continu see growth china replac high-end technolog
includ chrom mass spec fei electron microscop
guid suggest conserv outlook believ investor
like focu comparison believ
conserv guid strength past year exceed
expect guid org revenue
 ep estim
reflect org revenue growth rev/ep vs
rate thermo fisher scientif outperform price target
remain outperform-r given view compani life scienc tool
lst leader unmatch scale reach research lab market combin
number growth product serv key end-market also acquir view
consolid sizabl portion lst market patheon acquisit close
brammer also close believ potenti consolid contract
develop manufactur organ industri long term view
posit given sheer scale reput presenc lst market biopharma
academ channel industrial/environment diagnost deliv manag
forecast grow solidifi presenc emerg market asia-pacif
china revenu continu strength biopharma end-market view
sign slow near term inorgan growth continu remain
key prioriti next five year capit deploy
share current trade ev/ebitda slightli large-
mid-cap tool averag ev/ebitda given
impress growth deliv leverag biolog drug discoveri develop
product china emerg market tailwind still continu believ
continu hold posit lead lab tool suppli provid like continu
post strong growth expect trade premium large- mid-cap tool
averag deliv ev/ebitda deriv price target appli
multipl ebitda estim
primari risk price target includ
slowdown global budget research could caus downsid risk forecast
tighten budget govern academ fund could result lower revenu
rel estim furthermor restrict global budget could result shift focu
strategi growth could increas oper risk declin government spend
could risk downsid forecast growth nih spend
biopharma declin pose greatest risk tmo revenu declin biopharma fund
could highli impact revenu given third revenu lever biopharma
industri slowdown biopharma fund would result downsid risk estim
valuat biomolecul forecast ramp drug market mid-teen
estim hing prolifer drive use tmo bioprocess
equip mass spectromet instrument reagent character
scale diversif could backfir tmo size diversif
advantag compani consolid space pose signific challeng term
move needl growth perspect given size acquisit
alreadi done includ life pthn transact would ventur estim
deal size least grow north organ make signific move
market although asset might visibl street given limit public
asset larg number privat asset could potenti avail howev
pose risk street might appreci capabl asset enough
move needl
emerg market pose signific risk tmo revenu geopolit risk
emerg market could disrupt oper downsid risk valuat forecast
risk could countri region specif could also impact tmo strategi creat
higher barrier entri exist futur market local product reagent prefer
import oper numer intern market includ india
china eastern europ name
tmo exposur china could also pose concentr risk china repres
tmo revenu macroeconom impact chines market could lead declin
compani revenu regul chines polici could also caus restrict oper
lead lower activ china question remain china relat
detail headwind could emerg polici risk
 synergi may go plan tmo acquisit sizabl may go
plan could result integr risk lower-than-expect synergi integr
requir cultur process adapt synergi model forecast
risk estim remain integr unquantifi aspect target
forecast model margin eros could occur under-perform
increas risk amazon distribut busi like impact revenu
tmo laboratori product servic lp busi custom shown
will consid amazon vendor consum product expir
date beaker pipett expect amazon expertis logist suppli chain
allow amazon offer product competit cost thu impact lp revenu overal
dollar million except per share data
good sold
net incom continu op
sg sale
 sale
oper expens sale
compani report svb leerink estim
